Premium
Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda
Author(s) -
Lamoril Jérôme,
Andant Christophe,
Bogard Catherine,
Puy Hervé,
Gouya Laurent,
Pawlotsky JeanMichel,
Da Silva Vasco,
Soulé JeanClaude,
Deybach JeanCharles,
Nordmann Yves
Publication year - 1998
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.510270329
Subject(s) - medicine , porphyria cutanea tarda , hepatitis c virus , gastroenterology , hepatitis c , risk factor , flaviviridae , immunology , virus
Abstract From 1995 to 1997, we prospectively evaluated the prevalence of hepatitis C virus (HCV) RNA in 124 patients with porphyria cutanea tarda (PCT) from Northern France (83 sporadic and 41 familial PCT). Serum samples were analyzed for ferritin, transaminases, HCV antibodies, and HCV RNA. In addition, genotyping of HCV and searches for HCV infection risk factors (blood transfusion, iv drug abuse, and surgical intervention) were performed. Twenty‐six of 124 patients (21%; 95% CI: 13.9–28) were positive for serum HCV antibodies. All of them were also positive for HCV RNA. The prevalence of HCV infection was higher in the sporadic PCT group (26.5%, 22 out of 83) than in the familial PCT group (9.7%, 4 out of 41). Risk factors for hepatitis C infection were found to be significantly increased in the HCV‐positive group when compared with the HCV‐negative PCT group. In all HCV‐positive patients with a risk factor, the suspected date of exposure to the virus always preceded the clinical onset of PCT. The HCV genotype pattern in PCT patients was similar to that observed in nonporphyric HCV patients in western European countries. Serum ferritin level was increased in both HCV‐positive and HCV‐negative porphyric patients. Transaminase levels were significantly higher in HCV‐infected PCT patients. Sixty‐seven out of 124 patients were retrospectively studied for hepatitis G virus (HGV) infection. Six of these 67 patients (8.9%; 95% CI: 2.1–15.8) were positive for HGV RNA. None of the six HGV‐infected patients were positive for HCV RNA. The HGV‐infected patients did not differ statistically from those without HGV infection with regard to age, ferritin, transaminase levels, and PCT treatment. These results support the view that sporadic cases of HGV infection may occur frequently. This study of a large cohort of HCV and PCT patients further documents an increasing gradient in HCV prevalence from northern to southern Europe, and shows that HCV infection acts as a triggering factor of PCT. Finally, the HGV prevalence found in the PCT patients was comparable with that found in French blood donors, suggesting that HGV is not a PCT triggering factor.